Ovarian suppression with a gonadotropin-releasing hormone agonist does not alter insulin-stimulated glucose disposal

被引:10
作者
Cooper, Brian C.
Sites, Cynthia K.
Casson, Peter R.
Toth, Michael J.
机构
[1] Univ Vermont, Dept Obstet & Gynecol, Burlington, VT 05405 USA
[2] Univ Vermont, Dept Med, Burlington, VT 05405 USA
关键词
ovarian hormones; estrogen; insulin sensitivity; GnRH agonist;
D O I
10.1016/j.fertnstert.2006.11.045
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: Aging is associated with reduced tissue sensitivity to insulin. In women, these age-related changes may be accelerated by menopause. The effect of ovarian hormone deficiency on tissue insulin sensitivity in humans, however, has not been defined clearly. Thus, the goal of this study was to evaluate the effect of suppression of endogenous ovarian hormone production on insulin-stimulated glucose disposal. Design: Randomized, single-blind, placebo-controlled trial. Setting: General clinical research center. Patients: Thirteen healthy, nonobese premenopausal women. Intervention(s): Insulin-stimulated glucose disposal was determined by hyperinsulinemic (40 mU/m(2)/min) clamp during the early to midfollicular and midluteal phase of the menstrual cycle. Volunteers then received 2 months of treatment with the GnRH agonist (GnRHa) leuprolide acetate (n = 6) or placebo (n = 7) and were retested. Main Outcome Measure(s): Total, oxidative, and nonoxidative insulin-stimulated glucose disposal. Result(s): Because no effect of cycle phase was found on total, oxidative, or nonoxidative glucose disposal, pretreatment follicular and luteal phase values were averaged. Treatment with GnRHa had no effect on total glucose disposal (GnRHa: 1.0.6 +/- 0.9 to 10.8 +/- 0.9 vs. placebo: 10.2 +/- 0.7 to 10.4 +/- 1.0 mg/kg fat-free mass/min, P = .99). Similarly, there was no effect of GnRHa administration on oxidative (GnRHa: 2.77 +/- 0.58 to 3.89 +/- 0.58 vs. placebo: 2.74 +/- 0.42 to 3.33 +/- 0.62 mg/kg fat-free mass/min, P = .52; n = 6 and 6, respectively) or nonoxidative (GnRHa: 7.82 +/- 0.68 to 6.91 +/- 0.66 vs. placebo: 7.94 +/- 0.72 to 7.79 +/- 0.99 mg/kg fat-free mass/min, P = .59; n = 6 and 6, respectively) components of glucose disposal. Conclusion(s): Our results suggest that endogenous ovarian hormones do not regulate tissue responsiveness to insulin or intracellular pathways of glucose disposal.
引用
收藏
页码:1131 / 1138
页数:8
相关论文
共 50 条
  • [31] Ovarian hyperstimulation syndrome in the 21st century: the role of gonadotropin-releasing hormone agonist trigger and kisspeptin
    Thomsen, Lise
    Humaidan, Peter
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2015, 27 (03) : 210 - 214
  • [32] Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all'' strategy: a prospective multicentric study
    Griesinger, Georg
    Schultz, Laura
    Bauer, Thomas
    Broessner, Anke
    Frambach, Thorsten
    Kissler, Stefan
    [J]. FERTILITY AND STERILITY, 2011, 95 (06) : 2029 - U195
  • [33] Euploidy rates between cycles triggered with gonadotropin-releasing hormone agonist and human chorionic gonadotropin
    Thorne, Jeffrey
    Loza, Alexandra
    Kaye, Leah
    Nulsen, John
    Benadiva, Claudio
    Grow, Daniel
    Engmann, Lawrence
    [J]. FERTILITY AND STERILITY, 2019, 112 (02) : 258 - 265
  • [34] Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study
    Bodri, Daniel
    Guillen, Juan Jose
    Galindo, Anna
    Mataro, Daniel
    Pujol, Aida
    Coll, Oriol
    [J]. FERTILITY AND STERILITY, 2009, 91 (02) : 365 - 371
  • [35] Gonadotropin-releasing hormone agonist ovulation trigger-beyond OHSS prevention
    Castillo, Juan Carlos
    Haahr, Thor
    Martinez-Moya, Maria
    Humaidan, Peter
    [J]. UPSALA JOURNAL OF MEDICAL SCIENCES, 2020, 125 (02) : 138 - 143
  • [36] Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen
    Sundström, I
    Nyberg, S
    Bixo, M
    Hammarbäck, S
    Bäckström, T
    [J]. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1999, 78 (10) : 891 - 899
  • [37] A Rationale for Timing of Luteal Support Post Gonadotropin-Releasing Hormone Agonist Trigger
    Kol, Shahar
    [J]. GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 2019, 84 (01) : 1 - 5
  • [38] Induction of circulating monocyte chemoattractant protein-1 in women with gonadotropin-releasing hormone agonist
    Matsui, Sumika
    Yasui, Toshiyuki
    Uemura, Hirokazu
    Yamamoto, Satoshi
    Matsuzaki, Toshiya
    Tsuchiya, Naoko
    Yuzurihara, Mitsutoshi
    Kase, Yoshio
    Irahara, Minoru
    [J]. JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2011, 90 (02) : 227 - 234
  • [39] Danazol versus a gonadotropin-releasing hormone agonist as preoperative preparation for hysteroscopic metroplasty
    Fedele, L
    Bianchi, S
    Gruft, L
    Bigatti, G
    Busacca, M
    [J]. FERTILITY AND STERILITY, 1996, 65 (01) : 186 - 188
  • [40] Gonadotropin-releasing hormone agonist: A new approach to reversible contraception in female deer
    Baker, DL
    Wild, MA
    Connor, MM
    Ravivarapu, HB
    Dunn, RL
    Nett, TM
    [J]. JOURNAL OF WILDLIFE DISEASES, 2004, 40 (04) : 713 - 724